Press Release (ePRNews.com) - WELLESLEY, Mass. - Feb 14, 2019 - Projected growth of the global antihypertensives market to 2023 is attributed to the growing prevalence of hypertension, an increase in government programs for prescription drugs, and investments by key players in the development of novel therapies.
The global market for antihypertensives was valued at $26.3 billion in 2018 and is expected to reach $27.8 billion in 2023 at a compound annual growth rate of 1.1% during the forecast period, according to the report “Antihypertensives: Global Markets to 2023.”
Major players in the industry include Johnson & Johnson, Daiichi Sankyo Co. Ltd, Novartis AG, and others.
- The highest growth rate is projected for combination drugs due to their effectiveness, multiple patent exclusivities, and the growing preference of combination drugs over monotherapies in the treatment of hypertension.
- By region, North America holds the largest market share, with anticipated growth driven by the adoption of new hypertension guidelines that are projected to increase the number of patients diagnosed with hypertension.
- Asia-Pacific is forecast to experience the most growth, fueled by increasing awareness regarding hypertension management and public-private sector collaborations to provide affordable treatment in developing countries.
“Market growth has been spurred by the introduction of differentiated therapies with novel mechanisms of action, such as phosphodiesterase-5 inhibitors, stimulators of soluble guanylate cyclase, and endothelin receptor antagonists,” the report notes. “These provide powerful alternatives to currently prescribed antihypertensive drugs. The loss of patent exclusivity of blockbuster drugs and the increasing penetration of generics are market restraints.”
Novel Drug Molecules on the Rise
Following combination drugs, the second-largest market share is held by a segment that includes direct renin inhibitors, alpha blockers, phosphodiesterase-5 inhibitors, stimulators of soluble guanylate cyclase, endothelin receptor antagonists, vasodilators, and prostacyclin receptors. These other drug classes comprise a robust clinical pipeline that will boost growth.
Editors/reporters requesting analyst interviews should contact Eric Surber at email@example.com. Source :